Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Santen Pharmaceutical Co's current 5-Year Share Buyback Ratio was 4.50%.
SNPHF's 5-Year Share Buyback Ratio is ranked better than 98.72% of 701
companies
in the Drug Manufacturers industry
Industry Median: -2.4
vs SNPHF: 4.50
Santen Pharmaceutical Co (OTCPK:SNPHF) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Santen Pharmaceutical Co 5-Year Share Buyback Ratio Related Terms
SNPHF vs LLY, JNJ, ABBV: 5-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co 5-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's 5-Year Share Buyback Ratio falls into.
Santen Pharmaceutical Co 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of 4.50 mean?
Santen Pharmaceutical Co (SNPHF) has a 5-Year Share Buyback Ratio of 4.50 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Santen Pharmaceutical Co and its competitors. According to the industry distribution chart, Santen Pharmaceutical Co ranks #9 out of 701 companies in the Drug Manufacturers industry, placing it in the top 1.3%.
Is Santen Pharmaceutical Co's 5-Year Share Buyback Ratio too high?
Santen Pharmaceutical Co's current 5-Year Share Buyback Ratio is 4.50. Based on the distribution chart, Santen Pharmaceutical Co ranks #9 out of 701 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Santen Pharmaceutical Co has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's 5-Year Share Buyback Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #9 out of 701 companies for 5-Year Share Buyback Ratio. This places Santen Pharmaceutical Co in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 5-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current 5-Year Share Buyback Ratio is 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Santen Pharmaceutical Co (SNPHF) has a current 5-Year Share Buyback Ratio of 4.50. The stock's GF Value™ is $12.19, compared to a current price of $13.05 — trading 7.1% above its estimated fair value. The current 5-Year Share Buyback Ratio is 4.50. Santen Pharmaceutical Co's overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current 5-Year Share Buyback Ratio is 4.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.05 is trading 7.1% above its estimated GF Value™ of $12.19.
Key valuation signals for SNPHF:
5-Year Share Buyback Ratio: 4.50
GF Value™: $12.19 vs. price of $13.05 (7.1% above fair value)
No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
88GF Score
Get the complete analysis for SNPHF
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHF has been successfully added to your 
